Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 93-120

  Yu, Rosie Z ^a   Geary, Richard S ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Biotech drugs; Downstream effects; Pharmacodynamics; Pharmacokinetics; Pharmacological endpoint; Reduction of target mRNA; Reduction of target protein

Indexed keywords

EID: 84877916820     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch4     Document Type: Chapter

References (66)

1. Watson, J., and F. Crick. 1953. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 171: 737.
2. Lima, W.F., M. Venkatraman, and S.T. Crooke. 1997. The influence of antisense oligonucleotide-induced RNA structure on E. coli RNase H1 activity. J. Biol. Chem. 272 : 18191-18199.
3. Manoharan, M. 1999. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489 : 117-130.
4. Henry, S.P., R.S. Geary, R. Yu, and A.A. Levin. 2001. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Invest. Drugs 2 : 1444-1449.
5. Geary, R.S., J.M. Leeds, S.P. Henry, D.K. Monteith, and A.A. Levin. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design 12 : 383-393.
6. Leeds, J.M., R.S. Geary, S.P. Henry, J. Glover, W. Shanahan, J. Fitchett, T. Burckin, L. Truong, and A.A. Levin. 1997. Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 16 : 1689-1693.
7. Yu, R.Z., R.S. Geary, T. Ushiro-Watanabe, A.A. Levin, and S.L. Schoenfeld. 2001. Pharmacokinetic properties in humans. In: S.T. Crooke (Ed.), Antisense DrugTechnology: Principles, Strategies, and Applications. Marcel Dekker, Inc., New York, pp. 183-200.
8. Agrawal, S., J. Temsamani, W. Galbraith, and J. Tang. 1995. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28 : 7-16.
9. Zhang, R., R.B. Diasio, Z. Lu, T. Liu, Z. Jiang, W.M. Galbraith, and S. Agrawal. 1995. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (Gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49 : 929-939.
10. Sands, H., L.J. Gorey-Feret, A.J. Cocuzza, F.W. Hobbs, D. Chidester, and G.L.Trainor. 1994. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45 : 932-943.
11. Grindel, J.M., T.J. Musick, Z. Jiang, A. Roskey, and S. Agrawal. 1998. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev. 8 : 43-52.
12. Cossum, P.A., H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S.R. Owens, P.M.Markham, J.P. Shea, and S.T. Crooke. 1993. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267 : 1181-1190.
13. Cossum, P.A., L. Troung, S.R. Owens, P.M.Markham, J.P. Shea, and S.T. Crooke. 1994. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269 : 89-94.
14. Yu, R.Z., R.S. Geary, J.M. Leeds, T. Ushiro-Watanabe, M. Moore, J. Fitchett, J.Matson, T. Burckin, M.V. Templin, and A.A. Levin. 2001. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci. 90 : 182-193.
15. Glover, J.M., J.M. Leeds, T.G. Mant, D. Amin, D.L. Kisner, J.E. Zuckerman, R.S. Geary, A.A. Levin, and W.R. Shanahan, Jr. 1997. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282 : 1173-1180.
16. Sereni, D., R. Tubiana, C. Lascoux, C. Katlama, O. Taulera, A. Bourque, A. Cohen, B. Dvorchik, R.R. Martin, C. Tournerie, A. Gouyette, and P.J. Schechter. 1999. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. J. Clin. Pharmacol. 39 : 47-54.
17. Leeds, J.M., and R.S. Geary. 1998. Pharmacokinetic properties of phosphorothioate oligonucleotides in humans. In: S.T. Crooke (Ed.), Antisense Research and Applications. Springer, Heidelberg, pp. 217-231.
18. Phillips, J.A., S.J. Craig, D. Bayley, R.A. Christian, R.S. Geary, and P.L. Nicklin. 1997. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54 : 657-668.
19. Rifai, A., W. Byrsch, K. Fadden, J. Clark, and K.-H. Schlingensipen. 1996. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am. J. Pathol. 149 : 717-725.
20. Crooke, S.T., L.R. Grillone, A. Tendolkar, A. Garrett, M.J. Fratkin, J. Leeds, and W.H. Barr. 1994. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. Ther. 56 : 641-646.
21. Geary, R.S., O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, and A.A. Levin. 2001. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296 : 898-904.
22. Geary, R.S., T. Ushiro-Watanabe, L. Truong, S.M. Freier, E.A. Lesnik, N.B. Sioufi, H. Sasmor, M.Manoharan, and A.A. Levin. 2001. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296 : 890-897.
23. Zhang, R.W., R.P. Iyer, D. Yu, W.T. Tan, X.S. Zhang, Z.H. Lu, H. Zhao, and S. Agrawal. 1996. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther. 278 : 971-979.
24. Sewell, L.K., R.S. Geary, B.F. Baker, J.M. Glover, T.G.K. Mant, R.Z. Yu, J.A. Tami, and A.F. Dorr. 2002. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther. 303 : 1334-1343.
25. Zhang, R., H. Wang, and S. Agrawal. 2005. Novel antisense anti-MDM2 mixedbackbone oligonucleotides: Proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets 5 : 43-49.
26. Geary, R.S., R.Z. Yu, T. Watanabe, S.P. Henry, G.E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A.A. Levin. 2003. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31: 1419-1428.
27. Manoharan, M. 2004. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8: 570-579.
28. McKay, R.A., L.J. Miraglia, L.L. Cummins, S.R. Owens, H. Sasmor, and N.M. Dean. 1999. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-γ expression. J. Biol. Chem. 274 : 1715-1722.
29. Yu, R.Z., R.S. Geary, D.K. Monteith, J. Matson, L. Truong, J. Fitchett, and A.A. Levin. 2004. Tissue disposition of a 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 93 : 48-59.
30. Yu, R.Z., B. Baer, A. Chappel, R.S. Geary, E. Chueng, and A.A. Levin. 2002. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal. Biochem. 304 : 19-25.
31. Yu, R.Z., J. Matson, and R.S. Geary. 2001. Terminal elimination rates for antisense oligonucleotides in plasma correlate with tissue clearance rates in mice and monkeys. In: Annual Meeting of American Association of Pharmaceutical Scientists, Denver, Colorado.
32. Levin, A.A., R.S. Geary, J.M. Leeds, D.K. Monteith, R.Z. Yu, M.V. Templin, and S.P. Henry. 1998. The pharmacokinetics and toxicity of phosphorothioate oligonucleotides. In: J.A. Thomas (Ed.), Biotechnology and Safety Assessment. Taylor & Francis, Philadelphia, PA, pp. 151-175.
33. Watanabe, T.A., R.S. Geary, and A.A. Levin. 2004. In vitro protein binding and drug interaction studies of an antisense oligonucleotide (ASO), Isis 113715, targeting human Ptb1b mRNA. In: AAPS Annual Meeting and Exposition. American Association of Pharmaceutical Scientists, Baltimore, MD.
34. Davies, B., and T. Morris. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 : 1093-1095.
35. Grundy, J.S., R.Z. Yu, R.S. Geary, A.A. Levin, S. Zhao, A. Keyhani, and G. Piccirilli. 2002. Comparative singledose disposition of radiolabeled ISIS 104838 and ISIS 113715 in rat. In: Annual Meeting of Pharmaceutical Scientists, Toronto, Canada.
36. Geary, R.S., J.M. Leeds, J. Fitchett, T. Burckin, L. Troung, C. Spainhour, M. Creek, and A.A. Levin. 1997. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25 : 1272-1281.
37. Goodarzi, G., M. Watabe, and K. Watabe. 1992. Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm. Drug Dispos. 13 : 221-227.
38. Galluppi, G.R., M.C. Rogge, L.K. Roskos, L.J. Lesko, M.D. Green, D.W. Feigal, Jr., and C.C. Peck. 2001. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin. Pharmacol. Ther. 69 : 387-399.
39. Butler, M., R.A. McKay, I.J. Popoff, W.A. Gaarde, D. Witchell, S.F. Murray, N.M. Dean, S. Bhanot, and B.P. Monia. 2002. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51: 1028-1034.
40. Zellweger, T., H. Miyake, S. Cooper, K. Chi, B.S. Conklin, B.P. Monia, and M.E. Gleave. 2001. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298 : 934-940.
41. Yacyshyn, B.R., M.B. Bowen-Yacyshyn, L. Jewell, R.A. Rothlein, E. Mainolfi, J.A. Tami, C.F. Bennett, D.L. Kisner, and W.R. Shanahan. 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease. Gastroenterology 114 : 1133-1142.
42. Chi, K.N., E. Eisenhauer, L. Fazli, E.C. Jones, S.L. Goldenberg, J. Powers, and M.E. Gleave. 2004. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense to clusterin, in patients with localized prostate cancer prior to radical prostatectomy. In: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA.
43. Baker, B.F., and B.P. Monia. 1999. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta 1489 : 3-18.
44. Altmann, K.-H., D. Fabbro, N.M. Dean, T. Geiger, B.P. Monia, M. Muuler, and P. Nicklin. 1996. Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem. Soc. Trans. 24 : 630-637.
45. Baker, B.F., S.S. Lot, T.P. Condon, S. Cheng-Flournoy, E.A. Lesnik, H.M. Sasmor, and C.F. Bennett. 1997. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272 : 11994-12000.
46. Yu, R.Z., H. Zhang, R.S. Geary, M. Graham, L. Masarjian, K. Lemonidis, R. Crooke, N.M. Dean, and A.A. Levin. 2001. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296 : 388-395.
47. Zhang, H., J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N.M. Dean. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nature Biotechnol. 18 : 862-867.
48. Yu, R.Z., G. Riley, K. Hoc, T.A.Watanabe, J.Matson, S.Murray, S. Booten, S. Bhanot, B. Monia, and R.S. Geary. 2003. effect of treatment regimen on sub-organ pharmacodynamics of a 2′-MOE modified antisense oligonucleotide, Isis 116847, targeting putative protein tyrosine phosphatase (PTEN)mRNA in rats. In: AAPS Annual Meeting and Exposition. American Association of Pharmaceutical Scientists, Salt Lake City, UT.
49. Yu, R.Y., E.J. McArdle, G. Riley, K. Hoc, K.C. Nishihara, T.A. Watanabe, S.K. Pandey, S. Bhanot, and R.S. Geary. 2002. In vivo pharmacodynamics and sub-cellular distribution of a 2-MOE-modified antisense oligonucleotide (ASO), ISIS 116847, targeting putative protein tyrosine phosphatase (PTEN) mRNA in mice and rats. In: Annual Meeting of Society ofToxicology and Chemistry, Baltimore, Maryland.
50. Wei, N., J. Fiechtner, D. Boyle, A. Kavanaugh, S. Delauter, S. Rosengren, G.S. Firestein, J. Tami, R. Yu, and L. Sewell. 2003. Synovial biomarker study of ISIS 104838, an antisense oligodeoxynucleotide targeting TNF-alpha, in rheumatoid arthritis. In: 67th Annual Meeting of the American College of Rheumatology (ACR). October 23-28, Orlando, Florida, USA.
51. Graham, M.J., S.T. Crooke, K.M. Lemonidis, H.J. Gaus, M.V. Templin, and R.M. Crooke. 2001. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem. Pharmacol. 62 : 297-306.
52. Morris, M.J., W.P. Tong, C. Cordon-Cardo, M. Drobnjak, W.K. Kelly, S.F. Slovin, K.L. Terry, K. Siedlecki, P. Swanson, M. Rafi, R.S. DiPaola, N. Rosen, and H.I. Scher. 2002. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8 : 679-683.
53. Leeds, J.M., M.J. Graham, L. Troung, and L.L. Cummins. 1996. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235 : 36-43.
54. Bigelow, J.C., L.R. Chirin, L.A. Mathews, and J.J. McCormack. 1990. High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J. Chromatogr. Biomed. Appl. 533 : 133-140.
55. Zinker, B.A., C.M. Rondinone, J.M.Trevillyan, R.J. Gum, J.E. Clampit, J.F. Waring, N. Xie, D. Wilcox, P. Jacobson, L. Frost, P.E. Kroeger, R.M. Reilly, S. Koterski, T.J. Opgenorth, R.G. Ulrich, S. Crosby, M. Butler, S.F. Murray, R.A. McKay, S. Bhanot, B.P. Monia, and M.R. Jirousek. 2002. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA 99 : 11357-11162.
56. Liang, Y., M.C. Osborne, B.P. Monia, S. Bhanot, W.A. Gaarde, C. Reed, P. She, T.L. Jetton, and K.T. Demarest. 2004. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53 : 410-417.
57. Watts, L.M., V.P. Manchem, T.A. Leedom, A.L. Rivard, R.A. McKay, D. Bao, T. Neroladakis, B.P. Monia, D.M. Bodenmiller, J.X. Cao, H.Y. Zhang, A.L. Cox, S.J. Jacobs, M.D. Michael, K.W. Sloop, and S. Bhanot. 2005. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 : 1846-1853.
58. Crooke, R.M., M.J. Graham, K.M. Lemonidis, C.P. Whipple, S. Koo, and R.J. Perera. 2005. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46: 872-884.
59. Bradley, J.D., R. Crooke, L.L. Kjems, M. Graham, R. Leong, R. Yu, D. Paul, and M. Wedel. 2005. Hypolipidemic effects of a novel inhibitor of human APO-B 100 in humans. In: The American Diabetes Association's 65th Annual Meeting, San Diego, California.
60. Yacyshyn, B.R., W.Y. Chevy, J. Goff, B. Salzberg, R. Baerg, A.L. Buchman, J. Tami, R. Yu, E. Gibiansky, W.R. Shanahan, and Isis 2302-CS9 Investigators. 2002. Double blind, placebo controlled trial of the remission inducing and steroid-sparing properties of an ICAM-1 antisense oligodeoxynucleotide alicaforsen (ISIS 2302) in active steroid-dependent Crohn's disease. Gut 51(1):30-36.
61. Yuen, A.R., J. Halsey, G.A. Fisher, J.T. Holmlund, R.S. Geary, T.J. Kwoh, A. Dorr, and B.I. Sikic. 1999. Phase I study of an antisense oligonucleotide to protein kinase C-γ (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5 : 3357-3363.
62. Nemunaitis, J., J.T. Holmlund, M. Kraynak, D. Richards, J. Bruce, N. Ognoskie, T.J. Kwoh, R.S. Geary, F.A. Dorr, D. Von Hoff, and S.G. Eckhardt. 1999. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase c-alpha, in patients with advanced cancer. J. Clin. Oncol. 17 : 3586-3595.
63. Kjems, L. 2005. New targets for glycemic control protein-tyrosine-phosphatase-1B antisense inhibitor. In: American Diabetes Association's 65th Annual Meeting, San Diego, California.
64. Crooke, R. 2004. Second-generation antisense drug for cardiovascular disease demonstrates significant and durable reduc tions in cholesterol. In: 9th Drug Discovery Technology World Congress, Boston, MA.
65. Yu, R., L. Gibiansky, E. Gibiansky, and R.S. Geary. 2001. Population pharmacokinetics and pharmacodynamics of ISIS 2302 (Role of population analysis in drug development). In: ASCPT Annual Meeting, Orlando, Florida.
66. Yu, R.Z., J.Q. Su, J.S. Grundy, R.S. Geary, K.L. Sewell, A. Dorr, and A.A. Levin. 2003. Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. 13 : 57-66.